Angler Gaming levererar en fin rapport och bolagets fokus på kostnadskontroll betalar sig.
Redeye is optimistic about today’s news from Egetis Therapeutics that patients on Emcitate are assoc...
Train Alliance redovisade stigande omsättning och resultat under det andra kvartalet.
Angler Gaming levererade en kv2 2024-rapport över vår förväntan avseende lönsamhet.
Redeye saw a sales development roughly in line with what was expected.
Biosergen has together with Indian Alkem initiated patient studies with its drug candidate BSG005 fo...
Spago Nanomedical’s Phase I/IIa study, Tumorad-01, is progressing with a steady OPEX base in line wi...
Ahead of Solwers' Q2 report on 30 August, we update our estimates to reflect two acquisitions conduc...
Redeye concludes that Q2 came in softer than Redeye had estimated, both in terms of lower sales and ...
Redeye comments on Flexion Mobile's Q2 2024 report, which was in line with our expectations.
Redeye saw a Q2 report showing sales slightly below our estimates, with a total growth of 31% for th...
Redeye comments on Thunderful Group’s Q2’24 report, which came in better than expected in terms of s...
Redeye sees a stable Q2 report from Teneo AI, with solid customer intake being the highlight.
Redeye states that Q2 came in weaker than it had expected, although the reason continues to be a ver...
Redeye reiterates its valuation following the Q2 2024 report, which was stronger than our expectatio...
Taaleri's Q2 2024 results were well above LSEG Data & Analytics consensus and our expectations, main...
'24e-'26e sales up 3-2% Volume growth to pick up in H2 Revised FVR of SEK 25-40 (20-35) Q2: Strong ...
Solid sales but slightly higher opex EBIT revised down by 4.
Lyckegård publicerade den 20 augusti år 2024 bolagets delårsrapport för det andra kvartalet år 2024.
Redeye returns with a more detailed take on the Q2 report, and we make some estimate changes that pu...
